SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: BDR who wrote (2232)4/6/1999 8:48:00 AM
From: Mary Kay  Respond to of 10280
 
Wow, blockbuster article!
Mary Kay



To: BDR who wrote (2232)4/6/1999 1:48:00 PM
From: Thomas M.  Respond to of 10280
 
... Sepracor's isomer R-fluoxetine, dubbed "Super Prozac," ... has three mechanisms of action (instead of one) ...

I have not heard this before.

... For perspective, look at big pharmaceutical Warner-Lambert (WLA), with $10.2 billion in 1998 revenues and a $57.1 billion capitalization -- compared to Sepracor's $3.17 billion cap. Imagine what trailblazer Sepracor might look like with even higher margins and more than $10 billion in sales ...

Nice comparison.

Tom